Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs - Clinton Health A...
The revolutionary HIV prevention tool, injectable lenacapavir, will be available at a cost of US$40 a year in 120 low- and middle-income countries starting in 2027, under a new partnership announced today between Dr. Reddy’s Laboratories and Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI.| Clinton Health Access Initiative
